At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Not Yet Opened 11-04 16:00:00 EST
3.97
+0.05
+1.32%
盘后3.97
+0.000.00%
16:25 EST
High4.03
Low3.84
Vol1.87K
Open4.03
D1 Closing3.92
Amplitude4.97%
Mkt Cap21.57M
Tradable Cap15.80M
Total Shares5.43M
T/O7.45K
T/O Rate0.05%
Tradable Shares3.98M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.